Explore

Trendline Trendline
Immutep Faces Securities Class Action Over Discontinued Cancer Trial

Immutep Faces Securities Class Action Over Discontinued Cancer Trial

Immutep Faces Securities Class Action Over Discontinued Cancer Trial
Trendline Trendline
Vyome Holdings Reports Q1 2026 Financial Results with Net Loss

Vyome Holdings Reports Q1 2026 Financial Results with Net Loss

Vyome Holdings Reports Q1 2026 Financial Results with Net Loss
Trendline Trendline
Innovent Biologics Shares Surge After $10.5 Billion Deal with Pfizer

Innovent Biologics Shares Surge After $10.5 Billion Deal with Pfizer

Innovent Biologics Shares Surge After $10.5 Billion Deal with Pfizer
Trendline Trendline
Vyome Holdings Reports Q1 2026 Financial Results and Strategic Developments

Vyome Holdings Reports Q1 2026 Financial Results and Strategic Developments

Vyome Holdings Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Pfizer and Innovent Biologics Forge $10.5 Billion Oncology Partnership, Boosting Innovent Shares

Pfizer and Innovent Biologics Forge $10.5 Billion Oncology Partnership, Boosting Innovent Shares

Pfizer and Innovent Biologics Forge $10.5 Billion Oncology Partnership, Boosting Innovent Shares
Trendline Trendline
Newron Pharmaceuticals to Engage Investors at June 2026 Conferences in New York and Virtually

Newron Pharmaceuticals to Engage Investors at June 2026 Conferences in New York and Virtually

Newron Pharmaceuticals to Engage Investors at June 2026 Conferences in New York and Virtually
Trendline Trendline
Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets

Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets

Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets
Trendline Trendline
Vyome Holdings Reports Q1 2026 Financial Results, Highlights Regulatory and Clinical Progress

Vyome Holdings Reports Q1 2026 Financial Results, Highlights Regulatory and Clinical Progress

Vyome Holdings Reports Q1 2026 Financial Results, Highlights Regulatory and Clinical Progress
Trendline Trendline
Vyome Holdings Reports Q1 2026 Financial Results with Net Loss and Strategic Developments

Vyome Holdings Reports Q1 2026 Financial Results with Net Loss and Strategic Developments

Vyome Holdings Reports Q1 2026 Financial Results with Net Loss and Strategic Developments
Trendline Trendline
ImmunoGenesis Appoints New Chief Medical Officer to Advance Cancer Therapies

ImmunoGenesis Appoints New Chief Medical Officer to Advance Cancer Therapies

ImmunoGenesis Appoints New Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Pfizer and Innovent Collaborate on $10.5B Cancer Treatment Development

Pfizer and Innovent Collaborate on $10.5B Cancer Treatment Development

Pfizer and Innovent Collaborate on $10.5B Cancer Treatment Development
Trendline Trendline
Pfizer and Innovent Biologics Announce $10.5 Billion Cancer Treatment Collaboration

Pfizer and Innovent Biologics Announce $10.5 Billion Cancer Treatment Collaboration

Pfizer and Innovent Biologics Announce $10.5 Billion Cancer Treatment Collaboration